BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more
BeiGene, Ltd. (ONC) - Total Assets
Latest total assets as of December 2025: $8.19 Billion USD
Based on the latest financial reports, BeiGene, Ltd. (ONC) holds total assets worth $8.19 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BeiGene, Ltd. - Total Assets Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BeiGene, Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
BeiGene, Ltd.'s total assets of $8.19 Billion consist of 76.1% current assets and 23.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.5% |
| Accounts Receivable | $865.08 Million | 10.6% |
| Inventory | $608.23 Million | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $62.70 Million | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BeiGene, Ltd.'s current assets represent 76.1% of total assets in 2025, an increase from 37.6% in 2013.
- Cash Position: Cash and equivalents constituted 55.5% of total assets in 2025, up from 33.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
BeiGene, Ltd. Competitors by Total Assets
Key competitors of BeiGene, Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
BeiGene, Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - BeiGene, Ltd. generates 0.65x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, BeiGene, Ltd. generates $ 3.50 in net profit.
BeiGene, Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.41 | 1.80 | 4.62 |
| Quick Ratio | 3.08 | 1.58 | 4.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.40 Billion | $ 1.78 Billion | $ 4.03 Billion |
BeiGene, Ltd. - Advanced Valuation Insights
This section examines the relationship between BeiGene, Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.07 |
| Latest Market Cap to Assets Ratio | 4.07 |
| Asset Growth Rate (YoY) | 38.3% |
| Total Assets | $8.19 Billion |
| Market Capitalization | $33.32 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BeiGene, Ltd.'s assets at a significant premium ( 4.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: BeiGene, Ltd.'s assets grew by 38.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BeiGene, Ltd. (2013–2025)
The table below shows the annual total assets of BeiGene, Ltd. from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.19 Billion | +38.30% |
| 2024-12-31 | $5.92 Billion | +1.99% |
| 2023-12-31 | $5.81 Billion | -9.00% |
| 2022-12-31 | $6.38 Billion | -25.26% |
| 2021-12-31 | $8.54 Billion | +52.40% |
| 2020-12-31 | $5.60 Billion | +247.38% |
| 2019-12-31 | $1.61 Billion | -28.33% |
| 2018-12-31 | $2.25 Billion | +114.98% |
| 2017-12-31 | $1.05 Billion | +157.87% |
| 2016-12-31 | $405.81 Million | +247.55% |
| 2015-12-31 | $116.76 Million | +117.76% |
| 2014-12-31 | $53.62 Million | +354.49% |
| 2013-12-31 | $11.80 Million | -- |